医学
病危
达帕格列嗪
器官功能障碍
心力衰竭
肾脏疾病
重症监护医学
急性肾损伤
危重病
2型糖尿病
内科学
糖尿病
败血症
内分泌学
作者
Caio A.M. Tavares,Luciano César Pontes Azevedo,Álvaro Réa-Neto,Niklas Söderberg Campos,Cristina Prata Amêndola,Amanda Christina Kozesinski-Nakatani,Paula Geraldes David-João,Suzana Margareth Lobo,Thiago Corsi Filiponi,Guacyra Margarita Batista de Almeida,Ricardo Reinaldo Bergo,Mário R. R. Guimarães-Júnior,Rodrigo C. Figueiredo,Joan R. Castro,Clewer J. Schuler,Glauco Adrieno Westphal,Ana Carla Carioca,Frederico Monfradini,Josué Nieri,Flavia M. O. Neves
出处
期刊：JAMA
[American Medical Association]
日期：2024-06-14
卷期号：332 (5): 401-401
被引量：10
标识
DOI：10.1001/jama.2024.10510
摘要
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors improve outcomes in patients with type 2 diabetes, heart failure, and chronic kidney disease, but their effect on outcomes of critically ill patients with organ failure is unknown.
科研通智能强力驱动
Strongly Powered by AbleSci AI
Grayball
MchemG
迟大猫
爱静静
back you up
开心岩
VDC
归尘
迷人秋烟
iNk
小白
andrele
竹筏过海
笔记本
遇上就这样吧
英勇的鼠标
小杨同学
YSM
zho
Xiaoxiao
皖公网安备34019202002308
